On June 14 of 2016, FDA has strengthened existing warnings about the risk of acute kidney injury associated with the SGLT2 inhibitors, canagliflozin (brand names Invokana, Invokamet) and dapagliflozin (brand names Farxiga, Xigduo XR).
Based on recent reports, The US Food and Drug Administration (FDA) issued a safety alert which revised the warnings in the drug labels to include info ...
Satisfied Users & 
Approved Press Releases
